Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)
NCT03158805
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Bipolar Disorder
Obesity
Interventions
DRUG:
LIRAGLUTIDE
OTHER:
Placebo
Sponsor
Lindner Center of HOPE